Literature DB >> 9297994

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

J A Staessen1, R Fagard, L Thijs, H Celis, G G Arabidze, W H Birkenhäger, C J Bulpitt, P W de Leeuw, C T Dollery, A E Fletcher, F Forette, G Leonetti, C Nachev, E T O'Brien, J Rosenfeld, J L Rodicio, J Tuomilehto, A Zanchetti.   

Abstract

BACKGROUND: Isolated systolic hypertension occurs in about 15% of people aged 60 years or older. In 1989, the European Working Party on High Blood Pressure in the Elderly investigated whether active treatment could reduce cardiovascular complications of isolated systolic hypertension. Fatal and non-fatal stroke combined was the primary endpoint.
METHODS: All patients (> 60 years) were initially started on masked placebo. At three run-in visits 1 month apart, their average sitting systolic blood pressure was 160-219 mm Hg with a diastolic blood pressure lower than 95 mm Hg. After stratification for centre, sex, and previous cardiovascular complications, 4695 patients were randomly assigned to nitrendipine 10-40 mg daily, with the possible addition of enalapril 5-20 mg daily and hydrochlorothiazide 12.5-25.0 mg daily, or matching placebos. Patients withdrawing from double-blind treatment were still followed up. We compared occurrence of major endpoints by intention to treat.
FINDINGS: At a median of 2 years' follow-up, sitting systolic and diastolic blood pressures had fallen by 13 mm Hg and 2 mm Hg in the placebo group (n = 2297) and by 23 mm Hg and 7 mm Hg in the active treatment group (n = 2398). The between-group differences were systolic 10.1 mm Hg (95% CI 8.8-11.4) and diastolic, 4.5 mm Hg (3.9-5.1). Active treatment reduced the total rate of stroke from 13.7 to 7.9 endpoints per 1000 patient-years (42% reduction; p = 0.003). Non-fatal stroke decreased by 44% (p = 0.007). In the active treatment group, all fatal and non-fatal cardiac endpoints, including sudden death, declined by 26% (p = 0.03). Non-fatal cardiac endpoints decreased by 33% (p = 0.03) and all fatal and non-fatal cardiovascular endpoints by 31% (p < 0.001). Cardiovascular mortality was slightly lower on active treatment (-27%, p = 0.07), but all-cause mortality was not influenced (-14%; p = 0.22).
INTERPRETATION: Among elderly patients with isolated systolic hypertension, antihypertensive drug treatment starting with nitrendipine reduces the rate of cardiovascular complications. Treatment of 1000 patients for 5 years with this type of regimen may prevent 29 strokes or 53 major cardiovascular endpoints.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9297994     DOI: 10.1016/s0140-6736(97)05381-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  533 in total

1.  Safety profile of lacidipine: update from a clinical trials database.

Authors:  L H Lindholm; P Tcherdakoff; A Zanchetti
Journal:  Drugs       Date:  1999       Impact factor: 9.546

2.  Possible mechanisms of action in the positive effect of beta blockers in heart failure.

Authors:  M J Kendall
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

3.  Isolated systolic hypertension: a radical rethink. It's a risk factor that needs treatment, especially in the over 50s.

Authors:  I B Wilkinson; D J Webb Christison; J R Cockcroft
Journal:  BMJ       Date:  2000-06-24

Review 4.  Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society.

Authors:  E O'Brien; A Coats; P Owens; J Petrie; P L Padfield; W A Littler; M de Swiet; F Mee
Journal:  BMJ       Date:  2000-04-22

Review 5.  Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?

Authors:  J M Wright; C H Lee; G K Chambers
Journal:  CMAJ       Date:  1999-07-13       Impact factor: 8.262

6.  Beta-blockers as first-line therapy for hypertension.

Authors:  G A Heckman; A Papaioannou; W Parkinson; C A Patterson
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

7.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 8.  [Reserpine-diuretic combinations in therapy of arterial hypertension. Current considerations].

Authors:  M Siepmann; W Kirch
Journal:  Med Klin (Munich)       Date:  1998-12-15

Review 9.  Recent advances in the management of hypertension in the elderly.

Authors:  F J Gennari; A S Gennari
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 10.  The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.

Authors:  C Sarti; M Kaarisalo; J Tuomilehto
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.